Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia

NCT01566162 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT01566162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01566162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2012
Completion date
November 30, 2013
Enrollment
191 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia